DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Must have received: anthracycline

prior treatment must have included an anthracycline

Must have received: CD20-targeted agent (rituximab)

prior treatment must have included ... rituximab (or another CD20-targeted agent)

Cannot have received: autologous stem cell transplant

Exception: allowed if >100 days prior to D0

Autologous stem cell transplant (ASCT) within <100 days prior to D0

Cannot have received: CAR-T cell therapy

Exception: allowed if >28 days prior to D0

Chimeric antigen receptor T cell (CAR-T) therapy within <28 days prior to D0

Cannot have received: chemotherapy

Exception: allowed if >28 days or >5 half-lives prior to D0

Chemotherapy ... within 28 days of D0 or 5 half-lives, whichever is shorter

Cannot have received: immunotherapy

Exception: allowed if >28 days or >5 half-lives prior to D0

Immunotherapy ... within 28 days of D0 or 5 half-lives, whichever is shorter

Cannot have received: radiotherapy

Exception: allowed if >14 days prior to D0

Radiotherapy within 14 days of day 0

Cannot have received: investigational agent

Exception: allowed if >28 days or >5 half-lives prior to D0

investigational agent treatment within 28 days of D0 or 5 half-lives, whichever is shorter